Human platelets express two thrombin receptors, protease activated receptor (PAR) 1 and PAR4. Recently we reported 3.7-fold increased PAR4-mediated aggregation kinetics in platelets from black subjects compared to white subjects. We now show that platelets from blacks (n=70) express 14% more PAR4 protein than whites (n=84), but this difference is not associated with platelet PAR4 function. Quantitative trait locus analysis identified three common SNPs in the PAR4 gene (F2RL3) associated with PAR4-induced platelet aggregation.
Introduction
Race/ethnicity is an important factor in determining the outcome of coronary heart disease (CHD). Compared to patients of white race/ethnicity, blacks have a 2-fold higher incidence of CHD, and black race/ethnicity is an independent predictor of worse survival after CHD events even when confounding demographic, socioeconomic, and clinical factors are considered.
1,2 Acute coronary events like myocardial infarction (MI) occur when an occlusive platelet thrombus forms at the site of a ruptured atherosclerotic plaque. There is heritable interindividual variation in platelet reactivity that may be relevant to these clinical events 3 and this heritability is greater in blacks than whites. [4] [5] [6] However, there has been a paucity of literature considering racial differences in platelet function.
P2Y12 and thromboxane receptor inhibition with aspirin and thienopyridines are mainstays of anti-platelet therapy for arterial vascular disease. More recently, the protease activated receptor (PAR) 1 inhibitor, vorapaxar, was approved for the secondary treatment of patients with prior MI and peripheral vascular disease. Although PAR4 inhibitors have been developed, [7] [8] [9] none have been studied in humans. Thrombin signals through platelet PAR1 and PAR4. These receptors couple to Gq proteins leading to activation of phospholipase Cγ, hydrolysis of phosphoinositides and increased cytoplasmic calcium, resulting in activation of integrin α IIbβ3 and platelet aggregation. 10 There are cellular phenotypic differences between PAR1 and PAR4. [11] [12] [13] [14] [15] [16] [17] PAR1 has a higher affinity for thrombin, and Ca 2+ transients rise sharply after PAR1 activation with PAR1-activating peptide (PAR1-AP) followed by a fast return to baseline levels. PAR4 stimulation with PAR4-activating peptide (PAR4-AP) induces a more gradual but sustained rise in [Ca 2+ ] I , which accounts for the majority of intracellular calcium flux. 12 PAR1 blockade with vorapaxar leaves PAR4 as the only means by which thrombin can
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From activate platelets. 18 PAR4 inhibition has a potential therapeutic advantage of inhibiting the maximal thrombin effect while minimizing bleeding because PAR1 signaling remains intact. 19 We recently demonstrated a 3.7-fold increased PAR4-mediated aggregation kinetics and greater calcium mobilization in platelets from black subjects compared to white subjects, and that phosphatidylcholine transfer protein (PC-TP) partially accounted for this racial difference. 20 Our analyses also indicated a genomic contribution to platelet function that differs by race. PC-TP expression differences accounted for 18% of the racial difference in thrombin-induced PAR4-mediated platelet reactivity. We now report racially dimorphic SNPs in the PAR4 gene,
F2RL3
, that regulate PAR4 function and the inhibitory capacity of the PAR4 inhibitor, YD-3.
These findings have potential clinical significance because greater platelet-mediated thrombosis could contribute to the worse outcomes in blacks than whites after coronary events, and the clinical risks and benefits of vorapaxar and other PAR inhibitors by race are unknown.
Methods
The Platelet RNA and eXpression 1 (PRAX1) study and genotyping PRAX1 subjects. 20 Additional healthy, male and female subjects, self-identified as black or white race were recruited in Philadelphia (cohort 2) for platelet calcium and PAR inhibitor studies. These subjects were genotyped for rs773902 or rs2227346 using TaqMan SNP 
Platelet phenotyping
Platelet rich plasma was obtained from each participant and light transmission aggregometry was performed as described. 20, 21 We developed an integrated agonist response score (ARS) that allowed precise differentiation among subjects with the same maximal aggregation. The score is the weighted average, determined by principal component analysis, of the max and slope of the aggregation curve measured by light transmission aggregometry in response to one or more concentrations of agonist. The concentrations used were: 0.5 mg/ml arachidonic acid; comparing maximum MFI to the baseline MFI measured prior to platelet stimulation.
IP 3 quantification
The expression vectors pBJ-FLAG-PAR4120A-296F, pBJ-FLAG-PAR4120A-296V, and pBJ-FLAG-PAR4120T-296V were generated by site directed mutagenesis from pBJ-FLAG-PAR4120T-296F 25 
Inhibitor studies
Platelets were pre-incubated with the indicated concentrations of vorapaxar 26 (Axon Medchem,
Lindsley at Vanderbilt University) as previously described. 27 Aggregation was then quantified after stimulation with 5 μ M PAR1-AP or 100 μ M PAR4-AP.
Statistical analysis
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Multiple linear regression analysis was performed including the PAR4 protein level and the risk SNPs as explanatory variables and PAR4 reactivity as the dependent variable. To determine fraction of variance of PAR4 reactivity explained by PAR4 protein levels and F2RL3 genotype, PAR4 protein level was brought into the model first followed by rs773902 genotype. To test for an interaction between rs773902 and YD-3 we performed a linear regression using aggregation as the dependent variable and PAR4-AP concentration, YD3 concentration, and rs773902 genotype as dependent variables. All statistical analyses were implemented using the R statistical package, 28 SPSS v.19 (IBM, Armonk, NY, USA), or GraphPad Prism (GraphPad Software, La Jolla, CA, USA). The linkage disequilibrium (LD) heatmap was generated using the R packages LDheatmap and genetics. There was no substantive racial difference in the linkage analysis of the F2RL3 region.
Results
Racial difference in platelet PAR4 expression Figure 1A shows greater PAR4 reactivity in platelets from 70 black subjects compared to 84 white (p = 6.8 x 10 -9 ) in the PRAX1 study. Regardless of race, there appeared to be 3 groups of PAR4-AP responders: high (>70%), intermediate (~30% to ~60%) and low (<20%).
Such a finding would be consistent with an additive genetic effect, but first we considered whether quantitative differences in PAR4 protein expression might contribute to racial differences in platelet PAR4 reactivity. Using platelets from all 154 subjects we found that blacks had 9% higher mean F2RL3 mRNA levels (P = 0.043, Figure 1B ) and 14% PAR4 protein levels (P = 0.0427, Figure 1C ). Although these small racial differences in PAR4 expression did not seem adequate to explain the 3.7-fold faster platelet aggregation in blacks 20 or the apparent 3 response groups, we considered whether expression levels correlated with PAR4 reactivity but observed none ( Figure 1D ). In addition, multiple linear regression analysis showed PAR4
protein level explained only 0.2% of the observed variation in PAR4 reactivity and that PAR4
protein was not explanatory for PAR4 reactivity (P = 0.415).
F2RL3 loci associated with PAR4 reactivity
We next considered whether a qualitative (or functional) difference in PAR4 might contribute to the racial difference in PAR4 reactivity. Quantitative trait locus (QTL) analysis of the PRAX1 cohort identified three F2RL3 SNPs, rs773904, rs773903 and rs773902, associated with platelet PAR4 reactivity (P-values of 1.26 x 10 -14 , 1.26 x 10 -14 , 9.15 x 10 -16 , respectively) after accounting for race, age and sex ( Figure 2A ). Linear regression analysis indicated no association of PAR4 protein level with rs773904 (P = 0.491), rs773903 (P = 0.491) or rs773902
(P = 0.489). rs773904 and rs773903 are intronic ( Figure 2B ), whereas rs773902 is located in
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the second exon and alters residue 120 in the second transmembrane domain. The "G" allele of rs773902 encodes alanine (Ala) and the "A" allele encodes threonine (Thr). Since rs773902 is non-synonymous and in strong LD with the two intronic SNPs (Figure 2B ), we focused our subsequent analyses on rs773902. After controlling for protein level, the SNP rs773902 explains 48% of variability in PAR4 reactivity (by ANOVA partial sum of squares).
The allelic frequency of rs773902 in PRAX1 differed between self-identified blacks and whites (P= 4.31 x 10 -16 , Fisher's Exact). The frequency of the G allele was 37% in blacks and 81% in whites ( Figure 2C ). Conversely, the frequency of the A allele was 63% in black subjects but only 19% in whites. We queried the HGDP 24 to assess whether U.S. racial genotypes were similar to other geographic locations and found corresponding racial rs773902 allele frequencies: the A allele (most common in U.S. blacks) was most prevalent in sub-Saharan
Africa and Papua New Guinea; the G allele (most common in U.S. whites) was more prevalent elsewhere ( Figure 2D ).
PAR4
Thr/Ala dimorphism at residue 120 and Phe/Val at residue 296 significantly associate with platelet PAR4 function PAR4-mediated platelet aggregation significantly differed by rs773902 genotype in the whole cohort (P = 9.15 x 10 -16 ) ( Figure 3A ) and within black and white subjects (P = 4.3 x 10 -9
and P = 3.1 x 10 -8 respectively) ( Figure 3B ). Platelets from subjects homozygous for Thr120
(more common among blacks) achieved the highest average maximum aggregation in response to PAR4-AP, while platelets from subjects homozygous for Ala120 (more common among whites) achieved the lowest average maximum aggregation among both races. Heterozygotes showed an intermediate phenotype. F2RL3 rs773902 genotype showed no effect on the platelet aggregation response to arachidonic acid (P = 0.0614), ADP (P = 0.5656), collagenrelated peptide (P = 0.1639), α -CD9 antibody (P = 0.6923) or PAR1-AP (P = 0.2807) ( Figure   3C ). Further analyses of arachidonic acid-induced platelet aggregation data showed no Figure 1A ). 48 hours after transfection, cells were stimulated with PAR4-AP and IP 3 was quantified. Figure 4B shows that PAR4-Thr120-Phe296 generated more IP 3 than PAR4-Ala120-Phe296 (P = 0.01, two-tailed T test at 30s) and that Val296-containing variants showed less activity than either Phe296-containing variant. Absolute IP 3 quantification in pmol generated from each of the three 
The PAR4-Thr120 variant is resistant to pharmacological inhibition by YD-3
Recently there has been an increasing interest in the therapeutic potential of PAR inhibitors as anti-thrombotic agents. We sought to determine whether the common Ala120Thr PAR4 variant might affect pharmacological inhibition of either PAR1 or PAR4. As expected, vorapaxar efficiently inhibited platelet aggregation through PAR1 ( Figure 5A ) but had no effect on PAR4-induced platelet aggregation regardless of rs773902 genotype ( Figure 5B ). YD-3 is a synthetic, low molecular weight, non-peptide indazole derivative that specifically blocks PAR4-induced platelet aggregation. 7, 30 We found a significant interaction between genotype and YD-3
inhibitor on the PAR4-induced aggregation response (P = 0.02) ( Figure 5C ). Individuals homozygous for PAR4-Thr120 were resistant to up to 1 μM YD-3 inhibition, whereas platelets from PAR4-Ala120 homozygotes were inhibited by 0.5 μM YD-3; heterozygotes appeared to have an intermediate response.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
Discussion
There is a racial disparity in CHD outcomes and platelets from healthy black subjects are hyperreactive through the PAR4 thrombin receptor compared to platelets from whites. In the current work we investigated the genetic and molecular mechanisms that contribute to racial differences in human platelet function. The major findings were the identification of: (1) There is a pronounced variation of 0 to 100% in the platelet aggregation response to PAR4-AP in the PRAX1 cohort, with platelets from black subjects showing greater reactivity than platelets from whites. PC-TP was previously shown to account for a portion of this racial difference, but ~82% of the variance remained unexplained. We found platelets from blacks expressed an average of 14% more PAR4 protein than platelets from whites. Although a small change in a surface receptor expression could theoretically have a larger effect on platelet aggregation, several aspects of our data do not support this possibility. First, there was no correlation between protein levels and PAR4-mediated platelet reactivity. Second, regression analysis indicated the protein levels accounted for only 0.2% of the observed variation in PAR4 reactivity. Third, the distribution of protein levels ( Figure 1C) did not resemble the distribution of PAR4 reactivity ( Figure 1A ). For these reasons and because the three groups of PAR4
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Three SNPs within F2RL3 met genome-wide significance for associations with PAR4-mediated platelet reactivity. These SNPs map within 501 base pairs of one another and are in very strong linkage disequilibrium. Two of these three are intronic and we have not pursued their functionality. In addition to rs773902, we searched public databases and found reports of 10 other missense SNPs in F2RL3. However, each of these has a minor allele frequency of less than 1%, making it implausible that these could account for the association between rs773902 and platelet aggregation in our 154 subject PRAX1 study. Blacks in PRAX1 more commonly express the rs773902 Thr120 allele, whereas whites more commonly express the Ala120 allele. The similar allele frequencies by race between PRAX1 and the HGDP argue against a U.S.-specific finding, and suggest our data may apply more broadly to global populations.
Only two large genome-wide studies have been performed testing for associations with platelet function. The first (from Framingham and Johns Hopkins) did not use agonists that activate platelets through PAR1 or PAR4. 31 The second study was PRAX1. 32 We have been unable to identify prior GWAS "hits" in F2RL3 associated with clinical thrombotic disease, but most studies were under-represented with black patients. The Thr120 allele in the white population is only 16% and perhaps these studies were not powered to identify associations among relatively infrequent variants such as this. Muehlschlegel et al performed a candidate locus substudy of the CABG Genomics Program and reported an association between rs773857
and PAR4-AP mediated platelet P-selectin expression. This SNP is in the CPAMD8 gene, ~18 kb downstream of F2RL3, but has no linkage to the F2RL3 SNPs we have described in the current manuscript. 33 The rs773902 genotype was strongly associated with PAR4-induced platelet aggregation and calcium release but not with the platelet aggregation response to other
agonists, further supporting a PAR4-specific effect. A second amino acid-changing variant was identified, but only in black subjects. Transfection studies showed PAR4-Val296 traffics to the membrane but does not signal normally. Intriguingly, the valine for phenylalanine substitution functioned as a hypomorphic allele whose effect was dominant over the Thr120/Thr120 or Ala120/Thr120 variants. Because of the low frequency of this allele, it is difficult to make firm conclusions about its effect in human platelets.
To assess the biochemical effects of amino acid changes on downstream signaling events, we used 293 cells, which contain the appropriate components (the Gq pathway) and have been a standard in the platelet biology field. [34] [35] [36] Using PAR4-AP-induced IP 3 generation, an important PAR4 signaling molecule, 11, 37 over-expression of the PAR4 variants demonstrated differing signaling capacities. A potential limitation of these experiments is that 293 cell typespecific effects may not apply to platelets. Unfortunately, we determined megakaryocyte-like cell lines (Meg-01 and HEL) express endogenous PAR4, prohibiting unambiguous interpretation of transfection data. Nevertheless, taken together, the simplest explanation for these genetic and cell biologic studies is that these functional variants alter platelet function.
The mechanism by which F2RL3 variants affect function is unclear, but our data raises a number of hypotheses. The greater Ca 2+ flux in platelets and enhanced IP 3 generation in 293 cells expressing PAR4-Thr120 suggests greater Gq-induced activation of PLCβ. Brian Kobilka and colleagues have shown in other seven-transmembrane G-protein coupled receptors, the transmembrane core of the protein undergoes conformational changes upon activation, affecting G-protein interaction. 38 In addition, a Thr (polar) substitution for Ala (nonpolar) at residue 120 may affect the interaction between the receptor and cholesterol and possibly affect both dimerization and ligand affinity. 39 Regarding the less common Phe296Val variant in transmembrane helix 6, this residue is predicted to lie in the ligand binding pocket of GPCR structures, and a valine substitution is predicted to alter ligand binding properties pathway. In addition to blocking PAR4-but not PAR1-induced platelet aggregation, 7, 30 YD-3 also blocks thrombin-induced platelet recruitment and smooth muscle cell proliferation, as well as neutrophil-induced platelet aggregation. 7, 40, 41 Oral YD-3 also attenuates intimal thickening in a rat carotid balloon injury model. 41 We are unaware of prior assessment of a pharmacogenetic interaction between YD-3 (or any PAR inhibitor) and rs773902 for PAR4-induced platelet aggregation. Our data demonstrate a potent interaction between the PAR4 Ala120Thr variant and YD-3 inhibition of PAR4-induced platelet aggregation. We hypothesize that YD-3 induces conformational changes in PAR4, and the extent of the conformational change is regulated by the amino acid at residue 120. Crystal structure data of the two receptor isoforms with YD-3 may help elucidate the basic molecular mechanism of this pharmacogenetic effect.
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